Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic and Pharmacodynamic Investigation of Galeterone in Metastatic Castration-Resistant Prostate Cancer
2013-003865-32Phase 2Terminated
- Sponsor
- Tokai Pharmaceuticals, Inc.
- Start
- Oct 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of galeterone in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Tokai Pharmaceuticals, Inc. Primary endpoints: Safety and Change in PSA concentration from baseline. Started Oct 2013; status: terminated.
02
Drugs
galeterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2013-003865-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003865-32.